peptide mapping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Brazilian roads are the primary carriers of freight and passenger traffic. The road system totaled 2,000,000 km (1,242,742 mi) in 2023, ranking fourth largest by size globally. The total of paved roads increased from 35,496 km (22,056 mi) in 1967 to 215,000 km (133,595 mi) in 2018. Brazil's railway system has been declining since 1945, when emphasis shifted to highway construction. The country's total railway track length was 30,576 km (18,999 mi) in 2015, as compared with 31,848 km (19,789 mi) in 1970, making it the ninth largest network in the world. Most of the railway system belonged to the Federal Railroad Network Corporation (RFFSA), which was privatized in 2007. The São Paulo Metro began operating on 14 September 1974 as the first underground transit system in Brazil. There are over 4,900 airports and airfields in Brazil, second only to the United States. São Paulo–Guarulhos International Airport, near São Paulo, is the largest and busiest airport with nearly 43 million passengers annually, while handling the vast majority of commercial traffic for the country. For freight transport, waterways are of importance. The industrial zones of Manaus can be reached only by means of the Solimões–Amazonas waterway (3,250 kilometers or 2,020 miles in length, with a minimum depth of six meters or 20 feet). The country also has 50,000 kilometers (31,000 miles) of waterways. Coastal shipping links widely separated parts of the country. Bolivia and Paraguay have been given free ports at Santos.
== Chemistry and materials science == Himalayan salt does not have lower levels of sodium than conventional table salt. Glass does not flow at room temperature as a high-viscosity liquid. Although glass shares some molecular properties with liquids, it is a solid at room temperature and begins to flow only at hundreds of degrees above room temperature. Old glass which is thicker at the bottom than at the top comes from the production process, not from slow flow; no such distortion is observed in other glass objects of similar or even greater age. Diamonds are not generally formed from compressed coal. Most natural gem diamonds formed in the conditions of extreme heat and pressure, commonly about 150 to 200 kilometers (93 to 124 mi) below the surface, and were later brought upward by kimberlite eruptions. Coal, by contrast, is a sedimentary deposit formed from buried plant remains, and is unlikely to migrate below 3.2 kilometers (2.0 mi) through geological processes. Because many diamonds are billions of years old, whereas the first land plants appeared much later, coal was not the source material for most natural diamonds. Neither "tin" foil nor "tin" cans still use tin as a primary material. Aluminum foil has replaced tin foil in almost all uses since the 20th century; tin cans now primarily use steel or aluminum as their main metal. There is no special compound added to the water in swimming pools that will reveal the presence of urine and catch those who urinate in the pool.
Stews have been made since ancient times. The world's oldest known evidence of stew was found in Japan, dating to around 5000 BC during the Jōmon period. They made seafood whose ingredients varied with the seasons. The food was cooked in large conical or rounded pots with tapered or pointy bottoms that sat well in the soil and ash of the bonfire or hearth. Amazonian tribes used the shells of turtles as vessels, boiling the entrails of the turtle and various other ingredients in them.
== Names == There has been some confusion about the biological effects of synephrine because of the similarity of this un-prefixed name to the names m-synephrine, Meta-synephrine and Neosynephrine, all of which refer to a related drug and naturally occurring amine more commonly known as phenylephrine. Although there are chemical and pharmacological similarities between synephrine and phenylephrine, they are nevertheless different substances. The confusion is compounded by the fact that synephrine has been marketed as a drug under numerous different names, including Sympatol, Sympathol, Synthenate, and oxedrine, while phenylephrine has also been called m-Sympatol. The synephrine with which this article deals is sometimes referred to as p-synephrine in order to distinguish it from its positional isomers, m-synephrine and o-synephrine. A comprehensive listing of alternative names for synephrine may be found in the ChemSpider entry (see Chembox, at right). Confusion exists over the distinctions between p- and m-synephrine. However, an examination of the references cited in support of this statement show that all the evidence for the presence of m-synephrine in C. aurantium derives from a report by Penzak and co-workers, whose Abstract states that m-synephrine was found in C.
=== Temple of the Theologic Virtues === On December 17, 1804, the Grand Lodge of Pennsylvania chartered the Temple of the Theologic Virtues, No. 103, (French: Le Temple des Vertus Théogales) at Havana. Joseph Cerneau, who had recently arrived from Saint-Domingue, was appointed its first Master. The Scottish Rite in these days only held 25 degrees, and Cerneau had achieved the 25th Degree that year. Cerneau's associates were Pierre Courroy and Pierre Bauschey. The original core of this Lodge were Frenchmen, who brought with them new ideas of the recent French Revolution. Cerneau was deported from Cuba in 1806, and wound up in the United States, where he established the Grand Consistory and the Cerneau Rite. The Temple of the Theologic Virtues remained intact, however, after his departure. On November 18, 1805, Reunion de Coeurs was added to the roster of French speaking Lodges seeking refuge from the Haitian Revolution, and reformed in Santiago de Cuba. In 1806, Concorde and Peseverance also established Lodges in Santiago de Cuba, where they adopted Spanish names. In Havana, the streets of Calle Amistad, Calle Concordia, and Calle Virtudes took their names from the Lodges that operated there. With the Napoleonic invasion of Spain in 1808, anti-French sentiment grew in Cuba. The French speaking Lodges began leaving the island with the refugees who had brought them.
Sources: en.wikipedia.org
Autolytic debridement: The most conservative type of debridement whereby the body's own natural defenses break down necrotic tissue via phagocytes and proteolytic enzymes. This method requires a moist environment and intact immune system. Mechanical debridement: Achieved through use of mechanical force to remove devitalized tissue (e.g. wet-to-dry dressing, pressurized wound irrigation, pulse-lavage); however, this process will remove both healthy and non-healthy tissue and is therefore considered a non-selective debridement method. Enzymatic debridement: A process of debridement in which enzymes such as proteinases or collagenases are applied topically to digest devitalized tissue. Depending on the agent, this process can be either selective or non-selective. Examples include trypsin, streptokinase-streptodornase combination, subtilisin, papain, and collagenase. Surgical debridement: Also known as sharp debridement, this is a process in which devitalized tissue is removed through use of surgical instruments such as scalpels, curettes, or surgical scissors. Surgical debridement can be done in a hospital bed, in an outpatient clinic, or in an operating room depending on the particular wound, risk of bleeding, and anesthesia requirements. Biological debridement: Also known as larval therapy, biological debridement is done through controlled application of sterile larvae (Lucilia sericata) to the wound bed. These larvae release proteolytic enzymes which dissolve necrotic tissue before then ingesting the now debrided tissue.
This table does not represent an exhaustive list, but demonstrates the various methods this medication is able to be administered. Flupentixol and melitracen is produced by numerous pharmaceutical companies worldwide, with many using oral tablets as the preferred route.
Louise Rummel, nurse and nursing educator (Manukau Institute of Technology) (born 1937). 22 August Denis Cameron, rugby union player (Mid Canterbury, Counties, national team) (born 1938). Michael Henderson, fencer, British Empire and Commonwealth Games bronze medallist (1962) (born 1935). 23 August – John Roy-Wojciechowski, Polish community leader and philanthropist (born 1933). 24 August – John Barnett, film and television producer (Footrot Flats: The Dog's Tale, Whale Rider, Sione's Wedding) (born 1945). 27 August Shane Christie, rugby union player (Tasman, Highlanders, Māori All Blacks) (born 1985). Dame Peggy Koopman-Boyden, gerontologist (University of Waikato) (born 1943). 29 August – Jay Shaw, philosopher (Victoria University of Wellington) (born 1941).
Centrifugation is a process that uses centrifugal force to separate mixtures of particles of varying masses or densities suspended in a liquid. When a vessel (typically a tube or bottle) containing a mixture of proteins or other particulate matter, such as bacterial cells, is rotated at high speeds, the inertia of each particle yields a force in the direction of the particles velocity that is proportional to its mass. The tendency of a given particle to move through the liquid because of this force is offset by the resistance the liquid exerts on the particle. The net effect of "spinning" the sample in a centrifuge is that massive, small, and dense particles move outward faster than less massive particles or particles with more "drag" in the liquid. When suspensions of particles are "spun" in a centrifuge, a "pellet" may form at the bottom of the vessel that is enriched for the most massive particles with low drag in the liquid. Non-compacted particles remain mostly in the liquid called "supernatant" and can be removed from the vessel thereby separating the supernatant from the pellet. The rate of centrifugation is determined by the angular acceleration applied to the sample, typically measured in comparison to the g-force. If samples are centrifuged long enough, the particles in the vessel will reach equilibrium wherein the particles accumulate specifically at a point in the vessel where their buoyant density is balanced with centrifugal force. Such an "equilibrium" centrifugation can allow extensive purification of a given particle.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.